Repligen Co. (NASDAQ:RGEN) Position Lessened by Bank of America Corp DE

Bank of America Corp DE cut its holdings in Repligen Co. (NASDAQ:RGEN - Free Report) by 36.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 277,947 shares of the biotechnology company's stock after selling 158,404 shares during the quarter. Bank of America Corp DE owned approximately 0.50% of Repligen worth $40,008,000 at the end of the most recent quarter.

Several other institutional investors have also recently modified their holdings of RGEN. Moody National Bank Trust Division grew its holdings in shares of Repligen by 10.2% during the fourth quarter. Moody National Bank Trust Division now owns 1,591 shares of the biotechnology company's stock worth $229,000 after buying an additional 147 shares in the last quarter. Park Avenue Securities LLC raised its stake in Repligen by 24.8% during the fourth quarter. Park Avenue Securities LLC now owns 3,901 shares of the biotechnology company's stock worth $561,000 after purchasing an additional 776 shares during the period. Integrated Investment Consultants LLC raised its position in shares of Repligen by 6.0% in the 4th quarter. Integrated Investment Consultants LLC now owns 2,360 shares of the biotechnology company's stock worth $340,000 after buying an additional 134 shares during the period. Artemis Investment Management LLP boosted its holdings in Repligen by 18.4% in the fourth quarter. Artemis Investment Management LLP now owns 153,832 shares of the biotechnology company's stock valued at $22,143,000 after acquiring an additional 23,905 shares during the last quarter. Finally, Diversify Wealth Management LLC grew its position in Repligen by 74.2% during the fourth quarter. Diversify Wealth Management LLC now owns 3,342 shares of the biotechnology company's stock valued at $518,000 after acquiring an additional 1,423 shares during the period. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts have recently weighed in on the stock. Royal Bank of Canada decreased their target price on shares of Repligen from $202.00 to $189.00 and set an "outperform" rating for the company in a research note on Wednesday, April 30th. TD Cowen initiated coverage on Repligen in a report on Monday, February 10th. They set a "buy" rating and a $200.00 price objective on the stock. JPMorgan Chase & Co. dropped their price target on shares of Repligen from $200.00 to $190.00 and set an "overweight" rating for the company in a research note on Tuesday, April 29th. StockNews.com upgraded shares of Repligen from a "sell" rating to a "hold" rating in a research note on Thursday, May 8th. Finally, HC Wainwright restated a "buy" rating and issued a $180.00 target price on shares of Repligen in a research note on Monday, May 5th. Six analysts have rated the stock with a hold rating and nine have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $173.25.

Insider Buying and Selling

In other news, Director Margaret Pax acquired 250 shares of Repligen stock in a transaction on Monday, March 17th. The stock was bought at an average cost of $150.69 per share, with a total value of $37,672.50. Following the completion of the purchase, the director now owns 1,043 shares of the company's stock, valued at $157,169.67. This represents a 31.53% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 1.20% of the company's stock.

Repligen Price Performance

NASDAQ:RGEN traded down $3.14 during midday trading on Wednesday, hitting $124.46. 44,864 shares of the stock were exchanged, compared to its average volume of 734,707. The business has a 50-day moving average price of $132.06 and a two-hundred day moving average price of $144.99. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26. The company has a market capitalization of $6.99 billion, a price-to-earnings ratio of -244.29, a P/E/G ratio of 4.54 and a beta of 1.21. Repligen Co. has a one year low of $102.97 and a one year high of $182.52.

Repligen (NASDAQ:RGEN - Get Free Report) last announced its quarterly earnings data on Tuesday, April 29th. The biotechnology company reported $0.39 earnings per share for the quarter, beating the consensus estimate of $0.35 by $0.04. The business had revenue of $169.17 million during the quarter, compared to analyst estimates of $163.65 million. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. The company's revenue was up 10.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.28 earnings per share. Sell-side analysts predict that Repligen Co. will post 1.72 EPS for the current year.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.